Investors Press Releases Choose Year All Items 2026 2025 2024 Search Press Releases Found 44 Results October 15, 2026 LB Pharmaceuticals to Participate in Upcoming Investor Events October 10, 2026 LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress October 9, 2026 LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4) October 6, 2026 LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment September 15, 2026 LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer September 3, 2026 LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer September 3, 2026 LB Pharmaceuticals to Participate in Upcoming September Investor Events August 11, 2026 LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update July 29, 2026 LB Pharmaceuticals Announces $150 Million Private Placement July 22, 2026 LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia 12345»
